Jefferies lowered the firm’s price target on Sutro Biopharma (STRO) to $4 from $7 and keeps a Buy rating on the shares. After having caught up with management, the firm updated its operating expense estimates based on early pipeline expectations, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers
- Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo
- Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
- Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results
- Sutro Biopharma enters research collaboration with FDA for ADC standards